Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24447320 | 0.86 | BTK (0.33) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL28755859 | 0.86 | BTK (0.33) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL29736205 | 0.84 | FAAH (0.38) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL2061868 | 0.80 | MEN1 (0.37) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL2340622 | 0.77 | KMT2A (0.38) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL23120791 | 0.77 | KMT2A (0.38) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL24571423 | 0.77 | CTSL (0.33) | MEN1MAPK1KMT2A | |
| SCHEMBL3197011 | 0.77 | KMT2A (0.34) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL1467682 | 0.77 | MEN1 (0.33) | MEN1MAPK1KMT2A | |
| SCHEMBL919128 | 0.77 | MEN1 (0.33) | MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4593836-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | Board of Regents, The University of Texas System (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-31 | — | — | US | disclosed |
| CN-117843641-B | NSD3 inhibitor and preparation method and application thereof | 和径医药科技（上海）有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024073283-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| WO-2021026803-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | GHSR 4768/4885MEN1 3777/4885MAPK1 2058/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | GHSR 4768/4885MEN1 3777/4885MAPK1 2058/4885 |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | NSD3, NCOA1, NR1D1 | GHSR 3133/4885MEN1 4039/4885MAPK1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.